Thoracic growing teratoma syndrome resection linked with good overall survival

Complete resection of thoracic growing teratoma syndrome (TGTS) is associated with good overall survival, although early detection and the clinician’s knowledge of systemic treatment options remain important factors, according to a study.

In this retrospective analysis, 29 patients who received surgery for TGTS were between 1999 and 2016, were included.

All patients in this study were treated with cisplatin-based chemotherapy. The median tumor size was 64.5 mm (range 10 mm -210 mm) and 10 patients had multilocalized TGTS. Complete resection was achieved in all cases.

The minor morbidity rate was 3.4%, the major morbidity rate was 6.9%, and the mortality rate was 0%.

In a long-term follow-up analysis of 28 patients with a median follow-up of 94 months (13-237 months), the 5-, 10-, and 15-year survival rates were 93%, 93%, and 84%, respectively.

Reference
Sponholz S, Chalepaki Ntelli K, Karaindros G, et al. Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome. World J Urol. 2020 Oct 31. DOI: 10.1007/s00345-020-03503-6. Epub ahead of print. PMID: 33128597.